Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study

Thorsten Zenz, Gerhard Glatting, Richard F Schlenk, Inga Buchmann, Hartmut Döhner, Sven N Reske, Donald Bunjes

Abstract

We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).

Original languageEnglish
JournalHaematologica
Volume91
Issue number2
Pages (from-to)285-6
Number of pages2
ISSN0001-5792
Publication statusPublished - 02.2006

Fingerprint

Dive into the research topics of 'Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study'. Together they form a unique fingerprint.

Cite this